Authored by: Jon Carson, Iain Farrance, John Getz, and Jon A. Rowley, RoosterBio, Inc. On 31-December-2019, Chinese officials alerted the World Health Organization of an outbreak of pneumonia cases in ... More
Originally Published: July 7, 2014 Updated October 2019 by: Taby Ahsan, Ph.D., Vice President of Analytical, Process & Product Development & Katrina Adlerz, Ph.D., Scientist, Development What is Population Doubling Level ... More
INTRODUCTION: Human Mesenchymal Stem/Stromal Cells, or hMSC, are key components of future therapeutics, engineered tissues, and medical devices and are currently in use in over 400 clinical trials (1). ... More
By Iain Farrance, Priya Baraniak, and Jon Rowley. RoosterBio. In this blog, we will present internal data and information on priming RoosterBio’s bone marrow-derived human MSCs (hMSC) with pro-inflammatory molecules ... More
We blogged recently about Mesenchymal Stem/Stromal Cell (MSC) Misconceptions that are holding the translational cell therapy field back, as identified by Donald Phinney and Luc Sensebé. Since we have come ... More
We blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cells that are impeding their clinical translation. While the development of robust and scalable manufacturing methods, reduced ... More
Human MSCs are the single most used cell source for tissue engineering and regenerative medicine applications, and clinical trials involving hMSCs have outpaced all other cell types in recent years ... More
Extreme cellular stress can trigger senescence, a mechanism protecting against malignant cell transformation. Adapted from: Kovacic J C et al. Circulation. 2011;123:1650-1660 We’ve mentioned several times on this blog how standardization of materials, ... More
Prolific Stem Cell and Cell Therapy Blogger Alexey Bersenev (@cells_nnm on Twitter) has recently written a post on his Cell Trials blog titled “Trends in cell therapy clinical trials 2011 ... More